A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer.
Ovarian serous adenocarcinoma identified during IVF: diagnostic approach, surgical management, and reproductive outcome.
A new weapon in the fight against ovarian cancer may soon help thousands of women who have run out of options.
If ever there was a time to be in Washington, D.C, it's NOW!
The 12th annual Ovarian Cancer National Alliance
“Celebration of Life” Conference
July 6th- 9th, 2009
Omni Shoreham Hotel in Washington, D.C.
Ovarian Cancer Biomarker Research Act
Ovarian Cancer Biomarker Bill Will be Introduced in the House of RepresentativesOvarian Cancer Biomarker Research ActBill # S.2569
Original Sponsor:Barbara Boxer (D-CA)Cosponsor Total: 16(last sponsor added 06/23/2008) 14 Democrats 1 Independents 1 Republicans
About This Legislation:A bill to amend the Public Health Service Act to authorize the Director of the National Cancer Institute to make grants for the discovery and validation of biomarkers for use in risk stratification for, and the early detection and screening of, ovarian cancer.
Urge your Representative to Sign On to H.R. 1230
Grassroots Action Center
Urge your Representative to Sign On to H.R. 1230
On February 26, 2009, Representative Doris O. Matsui (D-CA) formally introduced the Bone Marrow Failure Disease Research and Treatment Act of 2009 (H.R. 1230). This legislation would bring together the resources of several federal agencies to advance our understanding of and treatments for aplastic anemia, myelodysplastic syndromes, and PNH. We need your support now
Jon Lovitz Supports OCRF With New Comedy Club Opening
Lovitz will perform opening night at The Jon Lovitz Comedy Club, located on CityWalk at Universal Studios Hollywood. The club features a Hawaiian beach motif, complete with sand dunes, palm trees, and delicious food for club-goers, and boasts a three-story, 400 seat capacity in which to enjoy live music and stand-up comedy.
A long-time friend of Faith Kates Kogan, president of OCRF's Board of Directors and founder of NEXT Model Management, Lovitz has participated in several of OCRF's signature events throughout the years, including Super Saturday LA. NEXT Model Management will co-host the gala benefit.
"It feels good to be able to do something like that," Lovitz says of his support for OCRF. Referencing Gilda Radner and Madeline Kahn, he recognizes that many great women in comedy have been taken too soon from cancer. "The whole point is to raise money for a cure and also for early detection."
OCRF thanks Jon Lovitz for his ongoing support, and for all that he has done to spread awareness and raise funds to continue the progression of ovarian cancer research. We wish him the best of luck in his endeavor, and encourage everyone to stop by the club to enjoy a great night of entertainment.
6th Annual Marie S. Franck " Footsteps toward Hope Ovarian Cancer Walk"
You can make a difference in the fight against ovarian cancer. Walk in memory or walk for a survivor at the 6th annual Marie S. Franck Foosteps Toward Hope Ovarian Cancer Walk on May 2, 2009 at 8:30am at the Jones Beach Boardwalk, parking field #5.
All proceeds will benefit the Rosewell Park Cancer Institute in Buffalo. Help them break the $100,000 mark with this year's donations!
To sign up, call Sister Suzanne at St. Joseph's College in Patchogue at (631) 447-6581.
All proceeds will benefit the Rosewell Park Cancer Institute in Buffalo. Help them break the $100,000 mark with this year's donations!
To sign up, call Sister Suzanne at St. Joseph's College in Patchogue at (631) 447-6581.
March 26th, 2009 Loehmann's Fashion Funs Hope to benefit the OCRF-Ovarian Cancer Research Fund
On Thursday, March 26th, fashion-savvy, budget-minded shoppers can support Ovarian cancer research while receiving special savings on leading designer apparel for one day only, at any of the sixty-four Loehmann's stores across the country.
As part of its chain-wide Fashion Funds Hope in-store event, Loehmann's will offer an additional 15% discount above its standard 30-65% savings to any customer who donates five dollars to the Ovarian Cancer Research Fund (OCRF).
In addition, Loehmann's will make a contribution to OCRF of 5% of total purchases by donors.Loehmann's customers will be able to pick up information about ovarian cancer, from risk factors and symptoms to the three programs run by OCRF, at tables set up inside the stores that day.
March 26th, 2009 Loehmann's Store's host Fasion Funds Hope to benefit the OCRF
OCRF is pleased to announce that on March 26, Loehmann’s stores will host Fashion Funds Hope, a fun-filled day of shopping and savings to benefit the Ovarian Cancer Research Fund.
We invite you to help make this day a success by volunteering to represent OCRF at a Loehmann’s store location near you.
As a volunteer, you can help disseminate OCRF literature and encourage shoppers to donate in support of life-saving ovarian cancer research. Participate in Fashion Funds Hope, and organize a team of family and friends to help raise funds and awareness for ovarian cancer. With your help, we will make this day a nationwide success!
We invite you to help make this day a success by volunteering to represent OCRF at a Loehmann’s store location near you.
As a volunteer, you can help disseminate OCRF literature and encourage shoppers to donate in support of life-saving ovarian cancer research. Participate in Fashion Funds Hope, and organize a team of family and friends to help raise funds and awareness for ovarian cancer. With your help, we will make this day a nationwide success!
Upcoming Lecture " Advances in Gyn Oncology" given by Dr. Jeanine Villella
Dr. Jeannine Villella, Attending Physician, Division of Gyn Oncology at Winthrop University Hospital will be giving an evening lecture to the community on March 12, 2009 on the topic “Advances in Gyn Oncology.”
If interested in attending please contact : Julie Mischo RN, MSNCancer Care Coordinator
Winthrop University Hospital
Phone 516-663-4637
If interested in attending please contact : Julie Mischo RN, MSNCancer Care Coordinator
Winthrop University Hospital
Phone 516-663-4637
OCRF and GCF fund new ovarian cancer symptoms study
OCRF and GCF fund new ovarian cancer symptoms study
Study hopes to improve symptom recognition
New York (February 5, 2009) --- Today, the Ovarian Cancer Research Fund (OCRF), in partnership with the Gynecologic Cancer Foundation (GCF), announced that Barbara Goff, M.D., Director of Gynecologic Oncology at the University of Washington, has been named to lead the OCRF Ovarian Cancer Symptoms Study. The award was presented by OCRF Scientific Advisory Board Vice-Chair, Carmel Cohen, M.D., at the Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer™ in San Antonio, Texas.
The study builds on an original symptoms study conducted by Dr. Goff which formed the basis for the first national Consensus Statement on Ovarian Cancer Symptoms, issued in 2007. The grant will allow researchers to forge ahead in their efforts to develop a systematic symptoms screening process for ovarian cancer.
Dr. Goff, a leading expert in gynecologic cancer research, was chosen to receive the grant, which will be awarded over three years. She was selected by a committee assembled by the GCF and chaired by Thomas Herzog, M.D. The selection committee also included three members of the OCRF Scientific Advisory Committee.
Prior to the development of the Consensus Statement on Ovarian Cancer Symptoms, ovarian cancer was often referred to as the "silent killer." Dr. Goff's research led to an evidence-based list of symptoms associated with ovarian cancer. When ovarian cancer, the deadliest reproductive cancer, is detected early, it is 90% curable The three-year symptoms study will pilot a method of systematically collecting symptom information with the hope that a symptoms index can be developed for broad use in early ovarian cancer detection.
Dr. Cohen is Professor of Obstetrics and Gynecology at Mount Sinai Medical Center in New York City. "Based on early data, patients with seemingly early disease are included among those who present with new and otherwise unexplained symptoms," Dr. Cohen noted. "While this may not be typical of early ovarian cancer, attention to the symptom complex may still serve as 'early detection' and thereby allow better opportunity for disease control in a segment of the population who develop ovarian cancer. We look forward to the possibility that this study will answer this question."
Dr. Goff has spent years researching and writing about ovarian cancer and the discovery of an early detection method. A diagnostic tool for early detection is crucial since there is a significant difference in cure rates if ovarian cancer is found early. "Through the continuation of this vital research, we aim to debunk the myth that ovarian cancer is a 'silent disease,' and empower both physicians and women to be better equipped to recognize symptoms in their earliest stage," Dr. Goff said. "Huge progress has been made, and now it's time to take the next step."
###
The Ovarian Cancer Research Fund is a 501(c) 3 not-for-profit organization founded in 1994 with a mission to fund research to find a method of early detection and ultimately a cure for ovarian cancer. OCRF is the leading independent agency dedicated to advancing ovarian cancer research in the United States. For more information, visit www.ocrf.org.
The Gynecologic Cancer Foundation (GCF), founded by the Society of Gynecologic Oncologists in 1991, is a 501(c) 3 not-for-profit organization whose mission is to ensure public awareness of gynecologic cancer prevention, early diagnosis and proper treatment. In addition, the Foundation supports research and training related to gynecologic cancers. GCF advances this mission by increasing public and private funds that aid in the development and implementation of programs to meet these goals.
Study hopes to improve symptom recognition
New York (February 5, 2009) --- Today, the Ovarian Cancer Research Fund (OCRF), in partnership with the Gynecologic Cancer Foundation (GCF), announced that Barbara Goff, M.D., Director of Gynecologic Oncology at the University of Washington, has been named to lead the OCRF Ovarian Cancer Symptoms Study. The award was presented by OCRF Scientific Advisory Board Vice-Chair, Carmel Cohen, M.D., at the Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer™ in San Antonio, Texas.
The study builds on an original symptoms study conducted by Dr. Goff which formed the basis for the first national Consensus Statement on Ovarian Cancer Symptoms, issued in 2007. The grant will allow researchers to forge ahead in their efforts to develop a systematic symptoms screening process for ovarian cancer.
Dr. Goff, a leading expert in gynecologic cancer research, was chosen to receive the grant, which will be awarded over three years. She was selected by a committee assembled by the GCF and chaired by Thomas Herzog, M.D. The selection committee also included three members of the OCRF Scientific Advisory Committee.
Prior to the development of the Consensus Statement on Ovarian Cancer Symptoms, ovarian cancer was often referred to as the "silent killer." Dr. Goff's research led to an evidence-based list of symptoms associated with ovarian cancer. When ovarian cancer, the deadliest reproductive cancer, is detected early, it is 90% curable The three-year symptoms study will pilot a method of systematically collecting symptom information with the hope that a symptoms index can be developed for broad use in early ovarian cancer detection.
Dr. Cohen is Professor of Obstetrics and Gynecology at Mount Sinai Medical Center in New York City. "Based on early data, patients with seemingly early disease are included among those who present with new and otherwise unexplained symptoms," Dr. Cohen noted. "While this may not be typical of early ovarian cancer, attention to the symptom complex may still serve as 'early detection' and thereby allow better opportunity for disease control in a segment of the population who develop ovarian cancer. We look forward to the possibility that this study will answer this question."
Dr. Goff has spent years researching and writing about ovarian cancer and the discovery of an early detection method. A diagnostic tool for early detection is crucial since there is a significant difference in cure rates if ovarian cancer is found early. "Through the continuation of this vital research, we aim to debunk the myth that ovarian cancer is a 'silent disease,' and empower both physicians and women to be better equipped to recognize symptoms in their earliest stage," Dr. Goff said. "Huge progress has been made, and now it's time to take the next step."
###
The Ovarian Cancer Research Fund is a 501(c) 3 not-for-profit organization founded in 1994 with a mission to fund research to find a method of early detection and ultimately a cure for ovarian cancer. OCRF is the leading independent agency dedicated to advancing ovarian cancer research in the United States. For more information, visit www.ocrf.org.
The Gynecologic Cancer Foundation (GCF), founded by the Society of Gynecologic Oncologists in 1991, is a 501(c) 3 not-for-profit organization whose mission is to ensure public awareness of gynecologic cancer prevention, early diagnosis and proper treatment. In addition, the Foundation supports research and training related to gynecologic cancers. GCF advances this mission by increasing public and private funds that aid in the development and implementation of programs to meet these goals.
SEND A VIRTUAL CUPCAKE- Electrolux will donate $1.00 to help fight Ovarian Cancer
This Valentine’s Day when you send a virtual cupcake, Electrolux will donate $1 to help fight ovarian cancer.
Sixth International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
Sixth International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
The Ritz-Carlton New York, Battery ParkNew York, NYMar 20-21, 2009
The Ritz-Carlton New York, Battery ParkNew York, NYMar 20-21, 2009
Sood Makes Breakthrough in Ovarian Cancer Research
HOUSTON, TX - In a major breakthrough, which can dramatically increase survival chances of ovarian cancer patients, an Indian American scientist has identified two proteins whose presence increases the median survival rate by 11 years in patients with the disease.
A study of nearly 250 ovarian cancer patients by Dr Anil Sood, MD, Professor in the departments of Gynecologic Oncology and Cancer Biology at M D Anderson, along with other researchers, found that woman with high levels of two proteins named Dicer and Drosha in their tumor cells had a median survival rate of 11 years. While, in patients with low levels of one or both proteins about 40 percent of those studied had a median survival of less than three years.
Sood’s discovery marks a significant advance for an emerging area of basic science called RNA interference, which one day may transform medicine.
“What’s important is that Dicer and Drosha are critical to the process of RNA interference,” Anil Sood said.
read more: http://www.indiajournal.com/pages/event.php?id=5786
A study of nearly 250 ovarian cancer patients by Dr Anil Sood, MD, Professor in the departments of Gynecologic Oncology and Cancer Biology at M D Anderson, along with other researchers, found that woman with high levels of two proteins named Dicer and Drosha in their tumor cells had a median survival rate of 11 years. While, in patients with low levels of one or both proteins about 40 percent of those studied had a median survival of less than three years.
Sood’s discovery marks a significant advance for an emerging area of basic science called RNA interference, which one day may transform medicine.
“What’s important is that Dicer and Drosha are critical to the process of RNA interference,” Anil Sood said.
read more: http://www.indiajournal.com/pages/event.php?id=5786
Force upcoming " Chat-a-thon" Jan 29 th-Jan 31st
Date: January 29-January 31, 2009
Time : One minute after midnight on January 29 to one minute before midnight on January 31.
Location: The FORCE Chat Room
Check out our regular scheduled chats and come back on the 29th!
Visit our chat room now
Time : One minute after midnight on January 29 to one minute before midnight on January 31.
Location: The FORCE Chat Room
Check out our regular scheduled chats and come back on the 29th!
Visit our chat room now
CancerCare-Medical Update on Ovarian Cancer- February 26, 2009
Medical Update on Ovarian Cancer
Thursday, February 26, 2008
1:30 - 2:30 p.m.
Thursday, February 26, 2008
1:30 - 2:30 p.m.
This is a free Telephone Education Workshop for women living with ovarian
cancer, their families, friends and health care professionals provided by
CancerCare Connect where leading experts in oncology provide the most up
to date information over the telephone. Speakers for this workshop include
Carolyn D. Runowicz, MD, Ilana Cass, MD, and Patricia Spicer, MSW.
Workshop Topics:
Overview of Ovarian Cancer
Staging
Current Standard of Care
New Treatment Approaches
The Important Role of Clinical Trials
Controlling Symptoms and Pain
Communicating with Your Health Care Team
Quality-of-Life Concerns
Questions and Answers
Overview of Ovarian Cancer
Staging
Current Standard of Care
New Treatment Approaches
The Important Role of Clinical Trials
Controlling Symptoms and Pain
Communicating with Your Health Care Team
Quality-of-Life Concerns
Questions and Answers
How to register:
Call CancerCare at 1-800-813-HOPE(4673)
or
on-line using the following link: Medical Update on Ovarian Cancer
Call CancerCare at 1-800-813-HOPE(4673)
or
on-line using the following link: Medical Update on Ovarian Cancer
Juliana Marchesano, BSW, MPH Intern
Ovarian Cancer Program
NYSDOH Cancer Services Program
(518) 402-9065
Ovarian Cancer Program
NYSDOH Cancer Services Program
(518) 402-9065
Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells.
"Malignant" uterine perivascular epithelioid cell tumor, pelvic lymph node lymphangioleiomyomatosis, and gynecological pecomatosis in a patient with t
Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer.
Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library.
Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis.
14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients.
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary.
Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene.
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers.
Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases.
A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.
Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.
Insurers Accused Of Underpaying Patients. CBS Evening News: New York AG Investigates Whether Health Care Companies Perpetuated Fraud
http://www.cbsnews.com/video/watch/?id=4720000n
PEA-15 Induces Autophagy in Human Ovarian Cancer Cells and Is Associated with Prolonged Overall Survival
Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor
A Phase I Trial of Pemetrexed Plus Gemcitabine Given Biweekly with B-Vitamin Support in Solid Tumor Malignancies or Advanced Epithelial Ovarian Cancer
Association Study of Prostate Cancer Susceptibility Variants with Risks of Invasive Ovarian, Breast, and Colorectal Cancer
Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transiti
The L'Oreal Legends Gala Raised Over $4.3 Million to Benefit The Ovarian Cancer Research Fund (OCRF)
The Immune System and Cancer
It was not always clear to scientists that the immune system played a role in preventing and combating cancer. This idea was proposed in 1957, but the scientific evidence at the time only seemed to indicate that the immune system protected against pathogens like viruses and bacteria, but not against abnormal body cells like cancer cells. Researchers and doctors in the late 1900s noticed, however, that people with extremely weak or nonexistent immune systems had a greater risk of developing cancer than the average person. In addition, researchers have since noticed that patients with immune cells present in their tumors have a better prognosis than patients without immune cells in their tumors.
Immunosurveillance is a term used to describe the action of the immune cells, including T cells, as they move through the body and look for any abnormalities. When cells become mutated, they may appear to the immune cells as abnormal. The body then recognizes them as non-self or foreign. By eliminating cells that have become abnormal, the immune system helps to protect against cancer. However, if the cells mutate enough so that they are able to escape the surveillance mechanisms of the immune system, they may continue to reproduce as cancer cells. The process is a complex version of 'hide and seek' with major consequences.
As described in the previous pages, T cells recognize peptide antigens 'presented' on their cell surface. If pre-cancerous cells present abnormal proteins T cells will recognize these cells as abnormal. Conversely, pre-cancerous cells that the immune system does not recognize as abnormal, or is unable to kill, will survive and may proliferate to form a tumor.
There are various mechanisms that tumor cells may use to get around the immune defenses of the body. Many cancers produce chemical messengers that inhibit the actions of immune cells. Other cancers have defects in the way that antigens are presented on their cell surface. Other immune cells, called natural killer (NK) cells, play a special role in this case, however, because they notice when body cells no longer have present specific 'self' proteins on their surface and kill the abnormal cells. Additionally, some tumors grow in locations such as the eyes or brain, which are not regularly patrolled by immune cells.
The main goal of immunotherapy and cancer vaccines is to provide the immune system with the signals that it needs to recognize the cancer cells as abnormal. If successful, these strategies may allow the body to recognize and destroy cancer cells, even those that have been able to form a tumor.
For more-----http://www.cancerquest.org/index.cfm?page=4903
Immunosurveillance is a term used to describe the action of the immune cells, including T cells, as they move through the body and look for any abnormalities. When cells become mutated, they may appear to the immune cells as abnormal. The body then recognizes them as non-self or foreign. By eliminating cells that have become abnormal, the immune system helps to protect against cancer. However, if the cells mutate enough so that they are able to escape the surveillance mechanisms of the immune system, they may continue to reproduce as cancer cells. The process is a complex version of 'hide and seek' with major consequences.
As described in the previous pages, T cells recognize peptide antigens 'presented' on their cell surface. If pre-cancerous cells present abnormal proteins T cells will recognize these cells as abnormal. Conversely, pre-cancerous cells that the immune system does not recognize as abnormal, or is unable to kill, will survive and may proliferate to form a tumor.
There are various mechanisms that tumor cells may use to get around the immune defenses of the body. Many cancers produce chemical messengers that inhibit the actions of immune cells. Other cancers have defects in the way that antigens are presented on their cell surface. Other immune cells, called natural killer (NK) cells, play a special role in this case, however, because they notice when body cells no longer have present specific 'self' proteins on their surface and kill the abnormal cells. Additionally, some tumors grow in locations such as the eyes or brain, which are not regularly patrolled by immune cells.
The main goal of immunotherapy and cancer vaccines is to provide the immune system with the signals that it needs to recognize the cancer cells as abnormal. If successful, these strategies may allow the body to recognize and destroy cancer cells, even those that have been able to form a tumor.
For more-----http://www.cancerquest.org/index.cfm?page=4903
Carol's Cause Presents the Annual " Peaches 'N Cream Gala"
Carol’s Cause
PRESENTS
THE ANNUAL PEACHES ‘N CREAM GALA
to benefit gynecologic cancer research
HONORING
HON. ESTER BIVONA
Receiver of Taxes, Town of Huntington and an ovarian cancer survivor
EVA CHALAS MD, FACOG, FACS
Professor and Vice-Chair
Department of Obstetrics and Gynecology at Winthrop-University Hospital
MICHELLE DI BENEDETTO
Director Community Relations, Long Island, Citi and an ovarian cancer survivor
BARBARA ROSS LEE DO, FACOFP
VP for Health Sciences and Medical Affairs
NY College of Osteopathic Medicine, NYIT
Monday, November 17, 2008
Cocktails in the Library Room – 6:00 PM
Dinner, reception immediately following
Black tie optional
Westbury Manor
Jericho Turnpike
Westbury, New York
For ticket and journal ad information call 516 873 1267 (Joe) or 516 342 5751 (Marc)
Carol’s Cause is a 501 (c) (3) organization.
PRESENTS
THE ANNUAL PEACHES ‘N CREAM GALA
to benefit gynecologic cancer research
HONORING
HON. ESTER BIVONA
Receiver of Taxes, Town of Huntington and an ovarian cancer survivor
EVA CHALAS MD, FACOG, FACS
Professor and Vice-Chair
Department of Obstetrics and Gynecology at Winthrop-University Hospital
MICHELLE DI BENEDETTO
Director Community Relations, Long Island, Citi and an ovarian cancer survivor
BARBARA ROSS LEE DO, FACOFP
VP for Health Sciences and Medical Affairs
NY College of Osteopathic Medicine, NYIT
Monday, November 17, 2008
Cocktails in the Library Room – 6:00 PM
Dinner, reception immediately following
Black tie optional
Westbury Manor
Jericho Turnpike
Westbury, New York
For ticket and journal ad information call 516 873 1267 (Joe) or 516 342 5751 (Marc)
Carol’s Cause is a 501 (c) (3) organization.
All donations are tax deductible to the extent allowable by law.
"BRCAness" Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer As
Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
Introduction to Oxidation and Anti-oxidants-From Cancer Quest
Oxidation is the chemical process that causes metal to rust and apples to turn brown. When this same process happens inside your body, it can harm cells and tissues. Primarily, molecules called 'free radicals' are responsible for this oxidative damage. Free radicals can be contained in (or induced to form by) a variety of things including tobacco smoke, radiation (like sunlight or x-rays) and even the normal functioning of the human body. These molecules have properties that allow them to quickly interact with, and alter, other molecules. Targets of free radicals include DNA, lipids and proteins. These interactions cause severe problems for cells and ultimately the entire body.
Antioxidants refer to molecules that, as the name suggests, counteract oxidation. Examples of dietary antioxidants include vitamins C and E. Antioxidants are able to interact with and neutralize free radicals in vitro , improve health and prolong life in animals , and many studies are underway to investigate the potential of these compounds to prevent cancer in humans.
Antioxidants refer to molecules that, as the name suggests, counteract oxidation. Examples of dietary antioxidants include vitamins C and E. Antioxidants are able to interact with and neutralize free radicals in vitro , improve health and prolong life in animals , and many studies are underway to investigate the potential of these compounds to prevent cancer in humans.
Ovarian Cancer Awareness Stamp--PLEASE SIGN IN MEMORY OF Carolyn Benivegna
Together we can make an OvCa stamp a reality. We have been requesting an ovarian cancer awareness postage stamp annually since 2001 and need your help. If you would like to support our goals, please sign our online petition. We will submit a request to the U.S. Postal Service along with the signatures that share in our quest to make this a reality.
In memory of Carolyn Benivegna, survivors, family and friends of those touched by ovarian cancer, please click on the link and help us send our message through the U. S. Postal Service. http://www.ipetitions.com/petition/ovca2008/
Thank you.
Ovacome
www.ovacome.us
ovcasurvivor@verizon.net
In memory of Carolyn Benivegna, survivors, family and friends of those touched by ovarian cancer, please click on the link and help us send our message through the U. S. Postal Service. http://www.ipetitions.com/petition/ovca2008/
Thank you.
Ovacome
www.ovacome.us
ovcasurvivor@verizon.net
EVERYTHING YOU ALWAYS WANTED TO KNOW…
EVERYTHING YOU ALWAYS WANTED TO KNOW…ABOUT COMBINING WORK AND CANCER TREATMENT
Please save-the-date for the upcoming Balancing Cancer and Careers Seminar in Knoxville.
When:Wednesday, October 15, 20085:30 PM-7:30 PM
Where:Women's Basketball Hall of Fame700 Hall of Fame DriveKnoxville, TN 37915
What:A FREE interactive, educational seminar featuring expert advice and personal success stories.
Who:• Kate Sweeney, Executive Director, Cancer and Careers, will providepractical advice and concrete solutions for employeesaffected by cancer.• Holly Warlick, Breast Cancer Advocate and Associate Head Coach of the University of Tennessee’s Women’s Basketball Team, will appear as a guest speaker.• A local breast cancer survivor will share her experience navigating her career and her cancer treatment.• A noted local oncologist will discuss the value of working through treatment and a legal expert will address patient rights in the workplace.
RSVP:(865) 523-6126 or scondon@ywcaknox.com
The Balancing Cancer and Careers Seminar is a collaboration between Cancer and Careers, Roche, The YWCA of Knoxville and The Wellness Community of East Tennessee.
The L'Oreal Paris Hope Necklace
Simply Stunning.
The L'Oreal Paris Hope Necklace is a simple way for women everywhere to visibly and tangibly help in the fight against one of the most deadly women's cancers.
The necklace was designed by 2008 Swarovski Award for Accessory Design recipient Philip Crangi and features a double eternity ring design of cubic zirconia set in sterling silver.
One ring is worn for remembrance and one ring is worn as a symbol of hope for the future.
The two eternity rings are free floating and suspended from an 18" rolo link chain. Each ring is comprised of 21 channel set, 2mm brilliant cubic zirconias.
This necklace normally retails for $99 but is being offered for only $29.95 (plus $5.95 s&h) to support ongoing research to defeat this dreadful disease. Net profits (five dollars per sale) will benefit the Ovarian Cancer Research Fund.
L'Oreal Paris has proudly supported the Ovarian Cancer Research Fund since 1997 and has helped to raise over $14 million to find life-saving research. For more information, visit http://www.lorealcolorofhope.com/
Attorney/Ovarian Cancer Survivor gets probation and is suspended for Contempt for refusing to provide documentation from her doctor.
Attorney/Ovarian Cancer Survivor gets probation and is suspended for Contempt for refusing to provide documentation from her doctor.
She contended that her tardiness was largely the product of medical issues stemming from ovarian cancer; the "contempt," she said, was only the typical back-and-forth between an attorney and a judge. She was guilty only of "disagreeing with a judge."
Pollack called herself "a whistle-blower who defended whistle-blowers," who was now the subject of a broad, illegal retaliatory scheme.
"The court proceeding today could only be described as criminal," Pollack said. "Am I not a whistle-blower, judge? Am I not a whistle-blower?"
"You may be the world's best whistle-blower," Ross answered, "but it isn't relevant."
The judge ordered two years' probation and a 45-day suspension, but declined to fine Pollack.
Kellman could not be reached for comment.
Assistant U.S. Attorney Monica Ryan represented the prosecution. She declined to comment.
Asked outside the courtroom if she intended to appeal, Pollack answered, "Yes, absolutely -- the entire thing."
Ruth was diagnosed in 2003 with Ovarian Cancer. She suffers from lymphedema in both legs and feet which from time to time requires that she rest and elevate her legs to recover. Ruth is a civil rights attorney and have been a trial lawyer for 25 years.
Ruth has had a number of male judges demand that she supply them with a "note" from her doctor explaining why she need a day of rest during a multi week trial, an adjournment of a conference due to the sudden swelling of her legs and feet, etc.
Ruth has had her primary care doctor take time from her busy schedule to prepare such letters through the years.
Sadly, her word as an attorney and officer of the court is not good enough.
Ruth refused one judge, insulted and appalled at the cruelty of this requirement. She decided to take a stand so that others like her would be treated with the respect they are due.
She contended that her tardiness was largely the product of medical issues stemming from ovarian cancer; the "contempt," she said, was only the typical back-and-forth between an attorney and a judge. She was guilty only of "disagreeing with a judge."
Pollack called herself "a whistle-blower who defended whistle-blowers," who was now the subject of a broad, illegal retaliatory scheme.
"The court proceeding today could only be described as criminal," Pollack said. "Am I not a whistle-blower, judge? Am I not a whistle-blower?"
"You may be the world's best whistle-blower," Ross answered, "but it isn't relevant."
The judge ordered two years' probation and a 45-day suspension, but declined to fine Pollack.
Kellman could not be reached for comment.
Assistant U.S. Attorney Monica Ryan represented the prosecution. She declined to comment.
Asked outside the courtroom if she intended to appeal, Pollack answered, "Yes, absolutely -- the entire thing."
Ruth was diagnosed in 2003 with Ovarian Cancer. She suffers from lymphedema in both legs and feet which from time to time requires that she rest and elevate her legs to recover. Ruth is a civil rights attorney and have been a trial lawyer for 25 years.
Ruth has had a number of male judges demand that she supply them with a "note" from her doctor explaining why she need a day of rest during a multi week trial, an adjournment of a conference due to the sudden swelling of her legs and feet, etc.
Ruth has had her primary care doctor take time from her busy schedule to prepare such letters through the years.
Sadly, her word as an attorney and officer of the court is not good enough.
Ruth refused one judge, insulted and appalled at the cruelty of this requirement. She decided to take a stand so that others like her would be treated with the respect they are due.
THINK TEAL, TALK TEAL, WEAR TEAL ~ SAVE LIVES. Tuesday, September 23rd, 2008. "NATIONAL OVARIAN CANCER AWARENESS DAY".
Teal Tuesday, September 23rd, 2008. National Ovarian Cancer Awareness Day
Press Release---
For Immediate Release
Teal Tuesday, September 23rd, 2008. National Ovarian Cancer Awareness Day.
Khrissy Lupinacci from LI OCEANS Inc (Long Island Ovarian Cancer Education Advocacy Network & Support) launches a Nationwide Public Awareness Campaign calling September 23rd, the 3rd Tuesday of September “ Teal Tuesday”. Our goal is to promote public education and much needed awareness of the deadliest form of Gynecologic Cancer called Ovarian Cancer. Ovarian Cancer claims the lives of over 22,000 women each year, this year alone over 15,000 women will be diagnosed with this deadly disease.
Khrissy Lupinacci (a 6 year survivor of Ovarian Cancer and one of the founding members of LI OCEANS Inc) said, “September is National Ovarian Cancer Awareness month.” “ It is our hope that “ Teal Tuesday ” inspires millions of people to adopt this day to raise awareness of this deadly disease. “ We are in need of soldiers, it will take an army to fight this fight against Ovarian Cancer “ said Khrissy. “ We are in need of heros” our greatest asset in this fight against ovarian cancer is our caring and compassionate community at large.” We hope that individuals, busineses and corporations join us in our plight to save lives. “We ask for national and local partnerships to help execute this initiative and support this campaign, making the 3rd Tuesday of September “ Teal Tuesday”. We hope this campaign inspires individuals to join us in our fight and encourages grassroots activities within their own communities to “ think teal, talk teal, wear teal, save lives!
Saving lives, each and everyone of us has the power to save lives, to date there is not an effective nor 100 % accurate early detection test for Ovarian Cancer. We know that early detection can save lives, however, with the lack of an early screening test and lack of Ovarian Cancer Awareness, we are left with but one vital tool, our voice. Together we can educate one another and create much needed awareness. A Pap test does not detect Ovarian Cancer. You don’t need to be personally affected by Ovarian Cancer to help in the fight to educate, advocate and create awareness, you simply need to care. Educate yourself about the signs and symptons of Ovarian Cancer, call or visit your local or National Ovarian Cancer organization, arm yourself with education and awareness of the signs, symptoms and risk factors of the disease, spread the news.
Sadly the majority, 75 percent of women are diagnosed in the later stages of Ovarian Cancer; the five –year survival is only 30 percent.
LI OCEANS INC believes one is too many; we must educate and advocate so to eradicate this deadly disease. Please join us in saving lives.
We ask locally and nationally that others join us in our plight to create much needed awareness of this ruthless and relentless killer of women. On Tuesday September 23rd, please wear teal! Wear teal in honor of the thousands of beautiful women that are battling the disease, wear teal in memory of the precious lives of those who have lost their battle to this disease. Wear Teal to help raise public awareness of the often overlooked and unrecognized signs and symptoms of this disease. Wear Teal because you care about the thousands of Grandmothers, Mothers, Sisters and Daughters that will be diagnosed with Ovarian Cancer this year. Wear teal for the 22,000 women that will die from Ovarian Cancer this year. Wear teal, help save lives.
Teal Tuesday, the initiative to launch a national public awareness campaign to save hundreds, thousands of women from Ovarian Cancer. On September 23rd, Teal Tuesday please wear teal; tie teal ribbons or teal balloons within your community, place of business, office or front lawn. Encourage hospitals, businesses, companies, schools, churches, synagogues, restaurants, stores, corporations, government offices, employees and co-workers to wear teal. Contact newspapers, radio, and television. Encourage Members of Congress to participate & adopt this as an annual campaign. “ Our goal is that every woman is educated and made aware of the signs, symptoms and risk factors of Ovarian Cancer.” Said, Khrissy Lupinacci.
For Immediate Release
Teal Tuesday, September 23rd, 2008. National Ovarian Cancer Awareness Day.
Khrissy Lupinacci from LI OCEANS Inc (Long Island Ovarian Cancer Education Advocacy Network & Support) launches a Nationwide Public Awareness Campaign calling September 23rd, the 3rd Tuesday of September “ Teal Tuesday”. Our goal is to promote public education and much needed awareness of the deadliest form of Gynecologic Cancer called Ovarian Cancer. Ovarian Cancer claims the lives of over 22,000 women each year, this year alone over 15,000 women will be diagnosed with this deadly disease.
Khrissy Lupinacci (a 6 year survivor of Ovarian Cancer and one of the founding members of LI OCEANS Inc) said, “September is National Ovarian Cancer Awareness month.” “ It is our hope that “ Teal Tuesday ” inspires millions of people to adopt this day to raise awareness of this deadly disease. “ We are in need of soldiers, it will take an army to fight this fight against Ovarian Cancer “ said Khrissy. “ We are in need of heros” our greatest asset in this fight against ovarian cancer is our caring and compassionate community at large.” We hope that individuals, busineses and corporations join us in our plight to save lives. “We ask for national and local partnerships to help execute this initiative and support this campaign, making the 3rd Tuesday of September “ Teal Tuesday”. We hope this campaign inspires individuals to join us in our fight and encourages grassroots activities within their own communities to “ think teal, talk teal, wear teal, save lives!
Saving lives, each and everyone of us has the power to save lives, to date there is not an effective nor 100 % accurate early detection test for Ovarian Cancer. We know that early detection can save lives, however, with the lack of an early screening test and lack of Ovarian Cancer Awareness, we are left with but one vital tool, our voice. Together we can educate one another and create much needed awareness. A Pap test does not detect Ovarian Cancer. You don’t need to be personally affected by Ovarian Cancer to help in the fight to educate, advocate and create awareness, you simply need to care. Educate yourself about the signs and symptons of Ovarian Cancer, call or visit your local or National Ovarian Cancer organization, arm yourself with education and awareness of the signs, symptoms and risk factors of the disease, spread the news.
Sadly the majority, 75 percent of women are diagnosed in the later stages of Ovarian Cancer; the five –year survival is only 30 percent.
LI OCEANS INC believes one is too many; we must educate and advocate so to eradicate this deadly disease. Please join us in saving lives.
We ask locally and nationally that others join us in our plight to create much needed awareness of this ruthless and relentless killer of women. On Tuesday September 23rd, please wear teal! Wear teal in honor of the thousands of beautiful women that are battling the disease, wear teal in memory of the precious lives of those who have lost their battle to this disease. Wear Teal to help raise public awareness of the often overlooked and unrecognized signs and symptoms of this disease. Wear Teal because you care about the thousands of Grandmothers, Mothers, Sisters and Daughters that will be diagnosed with Ovarian Cancer this year. Wear teal for the 22,000 women that will die from Ovarian Cancer this year. Wear teal, help save lives.
Teal Tuesday, the initiative to launch a national public awareness campaign to save hundreds, thousands of women from Ovarian Cancer. On September 23rd, Teal Tuesday please wear teal; tie teal ribbons or teal balloons within your community, place of business, office or front lawn. Encourage hospitals, businesses, companies, schools, churches, synagogues, restaurants, stores, corporations, government offices, employees and co-workers to wear teal. Contact newspapers, radio, and television. Encourage Members of Congress to participate & adopt this as an annual campaign. “ Our goal is that every woman is educated and made aware of the signs, symptoms and risk factors of Ovarian Cancer.” Said, Khrissy Lupinacci.
National Ovarian Cancer Awareness Day, September 23rd, 2008
September is Ovarian Cancer Awareness Month.
National Ovarian Cancer Awareness Day on Long Island
National Ovarian Cancer Awareness Day on Long Island
Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer
The Kaleidoscope of Hope Foundation
KALEIDOSCOPE OF HOPE’S ANNUAL WALKATHONS – 2008
MORRIS – Sunday, September 14 LYNDHURST – Sunday, September 21AVON – Saturday, September 27
For one morning and 1, 3 or 5 miles, you have the opportunity to dramatically impact the lives of women and their families affected by ovarian cancer. By participating in our 9th Annual Walkathon Events you help support ovarian cancer research and early detection programs.
MORRIS – Sunday, September 14 LYNDHURST – Sunday, September 21AVON – Saturday, September 27
For one morning and 1, 3 or 5 miles, you have the opportunity to dramatically impact the lives of women and their families affected by ovarian cancer. By participating in our 9th Annual Walkathon Events you help support ovarian cancer research and early detection programs.
Watch Stand Up to Cancer TONIGHT September 5th, 2008
TUNE IN TONIGHT SEPTEMBER 5TH 8PM ET/PTSTAND UP TO CANCER
Over 50 of the most renowned personalities in TV, film, sports and music will come together to make history. In an unprecedented television event, NBC, ABC, and CBS will simultaneously devote 1 hour of commercial-free prime time to raise funds for the fight against cancer.
A spectacular line up of talent including Jennifer Aniston, James Taylor, Scarlett Johansson, Meryl Streep, David Cook, Christina Applegate, Lance Armstrong, Jack Black, Kirsten Dunst, Charles Barkley, America Ferrera, Halle Berry, Hilary Swank, Forrest Whitaker, Jimmy Fallon, Keanu Reeves * will make personal appearances on the show. These celebrities and more will educate you, move you and entertain you. They will also be on hand to answer your calls in the celebrity phone bank.
ONE NIGHT ONE STAGE
The premiere TV performance of “Just Stand Up” – the star studded charitable single in support of Stand Up To Cancer will be performed by legendary recording artists Mariah Carey, Beyonce, Mary J. Blige, Rihanna, Fergie, Sheryl Crow, Miley Cyrus, Melissa Etheridge, Ashanti, Natasha Bedingfield, Keyshia Cole, Ciara, Leona Lewis, LeAnn Rimes, and Carrie Underwood.
OVARIAN CANCER SURVIVORS GROUP DONATES $25,000 TO SBUMC
OVARIAN CANCER SURVIVORS GROUP DONATES $25,000 TO SBUMC FOR GYNECOLOGIC CANCER RESEARCH INITIATIVES
Gift Coincides With National Ovarian Cancer Awareness Month
STONY BROOK, N.Y., September 2, 2008 – Long Island OCEANS (Ovarian Cancer Education Advocacy Network & Support), an organization made up of gynecologic cancer survivors, donated $25,000 to Stony Brook University Medical Center to support research on the early detection and treatment of ovarian cancer and other gynecologic cancers. SBUMC cancer researchers have received continued support from L.I. OCEANS, including a grant for $25,000 in 2006.
Caption: Stony Brook University Medical Center received $25,000 from L.I. OCEANS (Ovarian Cancer Education Advocacy Network & Support) for gynecologic cancer research. Pictured from left: Eileen Tobin, OCEANS member; Denise Reilly, Administrator, Ambulatory Cancer Services, SBUMC; Theodore Gabig, M.D., Interim Director, Stony Brook University Cancer Center; Khrissy Lupinacci, an OCEANS founding member; Michael L. Pearl, M.D., Director, Division of Gynecologic Oncology, SBUMC; Chris Reynolds, OCEANS member; and Marylou Stewart, OCEANS founding member and Supervisor, Medical Photography, SBUMC. Credit: Jeanne Neville, Stony Brook University Media Services
******************************************************************************
Gift Coincides With National Ovarian Cancer Awareness Month
STONY BROOK, N.Y., September 2, 2008 – Long Island OCEANS (Ovarian Cancer Education Advocacy Network & Support), an organization made up of gynecologic cancer survivors, donated $25,000 to Stony Brook University Medical Center to support research on the early detection and treatment of ovarian cancer and other gynecologic cancers. SBUMC cancer researchers have received continued support from L.I. OCEANS, including a grant for $25,000 in 2006.
Ovarian cancer is the most deadly form of gynecologic cancer. According to the American Cancer Society, ovarian cancer claims the lives of more than 22,000 each year, and 15,000 women are diagnosed with the disease annually. The White House has declared September National Ovarian Cancer Awareness Month, and the Gynecologic Cancer Foundation calls September National Gynecologic Cancer Awareness Month.
“The search for better and more accurate diagnostics for early detection of gynecologic cancers, particularly for ovarian cancer, is central to our research,” says Michael L. Pearl, M.D., Director, Division of Gynecologic Oncology at SBUMC. “The grant from Long Island OCEANS will help further several research initiatives,” adds Dr. Pearl, emphasizing that because symptoms of ovarian cancer often do not occur until the disease is advanced, many women are not diagnosed early enough to help control or cure disease.
The goal of L.I. OCEANS is to create awareness among women regarding the early warning signs and symptoms of gynecologic cancers. The network provides support, resources, and education for women diagnosed with gynecologic cancers, as well as support for the advancement of disease research. L.I. OCEANS is promoting “Teal Tuesday,” September 23, as National Ovarian Cancer Awareness Day. The organization is appealing for people to wear teal in honor of the thousands of lives who have been touched by the disease.
The Division of Gynecologic Oncology at SBUMC is within the Department of Obstetrics, Gynecology and Reproductive Medicine. The Division provides comprehensive examinations, diagnostic services, and treatment for women with all forms of gynecologic cancer. Research is a major component of the Division. Patient services are provided at SBUMC, the Stony Brook University Cancer Center outpatient facility, and at Long Island Gynecologic Oncologists, P.C., with offices in Smithtown and Mineola.
Caption: Stony Brook University Medical Center received $25,000 from L.I. OCEANS (Ovarian Cancer Education Advocacy Network & Support) for gynecologic cancer research. Pictured from left: Eileen Tobin, OCEANS member; Denise Reilly, Administrator, Ambulatory Cancer Services, SBUMC; Theodore Gabig, M.D., Interim Director, Stony Brook University Cancer Center; Khrissy Lupinacci, an OCEANS founding member; Michael L. Pearl, M.D., Director, Division of Gynecologic Oncology, SBUMC; Chris Reynolds, OCEANS member; and Marylou Stewart, OCEANS founding member and Supervisor, Medical Photography, SBUMC. Credit: Jeanne Neville, Stony Brook University Media Services
******************************************************************************
Greg Filiano Media Relations Manager, School of MedicineStony Brook University Medical CenterLevel 5, Suite 9, Rm. 429Stony Brook, NY 11794-7538631-444-9343 gfiliano@notes.cc.sunysb.eduwww.stonybrook.edu/news
Kelly Confidential- Help Kelly & Electrolux Fight Ovarian Cancer
Limited Edition T-Shirt Designed by Kelly Ripa
In Support of National Ovarian Cancer Awareness Month ... Kelly Ripa Launches Premium Laundry Collection from Europe's Leading Premium Appliance Brand
NOCC Walk- Long Island Chapter- September 20th, 2008
SAVE THE DATE: NOCC Long Island chapter walk - September 20, 2008 - Wantagh Park, Wantagh, NY.
For More info contact Linda Rosen ( NY, Long Island NOCC Chapter)
Phone: 631-672-2027; nyli.nocc@ovarian.org
National Ovarian Cancer Awareness Month, 2008 -A Proclamation by the President of the United States of America
National Ovarian Cancer Awareness Month, 2008 A Proclamation by the President of the United States of America
During National Ovarian Cancer Awareness Month, we remember those whose lives have been affected by this deadly disease, and we underscore our commitment to battling ovarian cancer for the sake of women around the world.
Each year, thousands of American women are diagnosed with ovarian cancer. Many will lose their lives to this disease. Because ovarian cancer is often diagnosed at an advanced stage, it is vital for women to make regular visits to their doctors for screenings and to discuss risk factors and warning signs. Early detection is the best way to help doctors diagnose cancer before it has a chance to spread. It also makes treatment more effective and increases the chances for survival. I encourage all women to learn more about preventive measures and screening options that may help to save their lives.
America leads the world in medical research, and my Administration remains dedicated to the fight against ovarian cancer. I signed the "Gynecologic Cancer Education and Awareness Act of 2005," or "Johanna's Law," that helps to raise awareness among women and health care providers about female reproductive cancers. Additionally, the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention are conducting important research to help make the innovative advances we need in order to eradicate this disease. NIH's Cancer Genome Atlas is also helping researchers gain a greater understanding of the genetic sources of cancer. Together, we will continue building on our progress until there is a cure for cancer.
As we observe National Ovarian Cancer Awareness Month, we honor those who have fought this disease. We also recognize the compassionate caregivers, doctors, and researchers who are dedicated to preventing, detecting, and treating ovarian cancer.
NOW, THEREFORE, I, GEORGE W. BUSH, President of the United States of America, by virtue of the authority vested in me by the Constitution and the laws of the United States, do hereby proclaim September 2008 as National Ovarian Cancer Awareness Month. I call upon government officials, businesses, communities, health care professionals, educators, volunteers, and the people of the United States to continue our Nation's strong commitment to preventing and treating ovarian cancer.
IN WITNESS WHEREOF, I have hereunto set my hand this twenty-sixth day of August, in the year of our Lord two thousand eight, and of the Independence of the United States of America the two hundred and thirty-third.
GEORGE W. BUSH
During National Ovarian Cancer Awareness Month, we remember those whose lives have been affected by this deadly disease, and we underscore our commitment to battling ovarian cancer for the sake of women around the world.
Each year, thousands of American women are diagnosed with ovarian cancer. Many will lose their lives to this disease. Because ovarian cancer is often diagnosed at an advanced stage, it is vital for women to make regular visits to their doctors for screenings and to discuss risk factors and warning signs. Early detection is the best way to help doctors diagnose cancer before it has a chance to spread. It also makes treatment more effective and increases the chances for survival. I encourage all women to learn more about preventive measures and screening options that may help to save their lives.
America leads the world in medical research, and my Administration remains dedicated to the fight against ovarian cancer. I signed the "Gynecologic Cancer Education and Awareness Act of 2005," or "Johanna's Law," that helps to raise awareness among women and health care providers about female reproductive cancers. Additionally, the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention are conducting important research to help make the innovative advances we need in order to eradicate this disease. NIH's Cancer Genome Atlas is also helping researchers gain a greater understanding of the genetic sources of cancer. Together, we will continue building on our progress until there is a cure for cancer.
As we observe National Ovarian Cancer Awareness Month, we honor those who have fought this disease. We also recognize the compassionate caregivers, doctors, and researchers who are dedicated to preventing, detecting, and treating ovarian cancer.
NOW, THEREFORE, I, GEORGE W. BUSH, President of the United States of America, by virtue of the authority vested in me by the Constitution and the laws of the United States, do hereby proclaim September 2008 as National Ovarian Cancer Awareness Month. I call upon government officials, businesses, communities, health care professionals, educators, volunteers, and the people of the United States to continue our Nation's strong commitment to preventing and treating ovarian cancer.
IN WITNESS WHEREOF, I have hereunto set my hand this twenty-sixth day of August, in the year of our Lord two thousand eight, and of the Independence of the United States of America the two hundred and thirty-third.
GEORGE W. BUSH
Ovarian Cancer Action Network
Ovarian Cancer Action Network
New Legislation to Increase Funds for Cancer Research Introduced
Cancer Trust Fund Bill Introduced in House of Representatives
Ovarian Cancer to be a Major Focus
One of the last bills to be introduced before the Congressional recess was the Cancer Trust Fund bill, a piece of legislation that aims to fully fund cancer initiatives through the federal government. By raising the tax on cigarettes, Congress and cancer advocacy groups hope to accelerate the War on Cancer, declared in 1971. Since then the relative five year survival rate for ovarian cancer has increased from 38 percent to 45 percent, indicating that ovarian cancer needs more research, early detection and treatment. These issues, and others, are addressed in the Cancer Trust Fund bill.
The Ovarian Cancer Action Network is a program of the Ovarian Cancer National Alliance
910 – 17th Street, N.W. • Suite 1190 • Washington, DC 20006Telephone: 202-331-1332 • FAX: 202-331-2292 http://www.ovariancancer.org
New Legislation to Increase Funds for Cancer Research Introduced
Cancer Trust Fund Bill Introduced in House of Representatives
Ovarian Cancer to be a Major Focus
One of the last bills to be introduced before the Congressional recess was the Cancer Trust Fund bill, a piece of legislation that aims to fully fund cancer initiatives through the federal government. By raising the tax on cigarettes, Congress and cancer advocacy groups hope to accelerate the War on Cancer, declared in 1971. Since then the relative five year survival rate for ovarian cancer has increased from 38 percent to 45 percent, indicating that ovarian cancer needs more research, early detection and treatment. These issues, and others, are addressed in the Cancer Trust Fund bill.
The Ovarian Cancer Action Network is a program of the Ovarian Cancer National Alliance
910 – 17th Street, N.W. • Suite 1190 • Washington, DC 20006Telephone: 202-331-1332 • FAX: 202-331-2292 http://www.ovariancancer.org
11th Annual Ovarian Cancer National Alliance Conference
Creating Currents of Change
July 8-10, 2008 –Washington, DC
July 8-10, 2008 –Washington, DC
Ovarian Cancer Action Network- Call in date July 10th, 2008
Call-In Day Thursday, July 10
Ask your elected officials to support ovarian cancer research
On Thursday, July 10, ovarian cancer survivors from across the country will be criss-crossing Capitol Hill educating Congress on the need for more ovarian cancer research funding. If you can't be in Washington, D.C., you can still participate in Capitol Hill Day by calling your three elected officials and urging them to support $25 million for the Ovarian Cancer Research Program in the Department of Defense Appropriations bill.
To see if your Member of Congress signed the letter supporting this request, see here (Senate ) and here (House).
To prepare to call your elected official, click the "take action" link at the top of this e-mail and enter your zip code when prompted
Ask your elected officials to support ovarian cancer research
On Thursday, July 10, ovarian cancer survivors from across the country will be criss-crossing Capitol Hill educating Congress on the need for more ovarian cancer research funding. If you can't be in Washington, D.C., you can still participate in Capitol Hill Day by calling your three elected officials and urging them to support $25 million for the Ovarian Cancer Research Program in the Department of Defense Appropriations bill.
To see if your Member of Congress signed the letter supporting this request, see here (Senate ) and here (House).
To prepare to call your elected official, click the "take action" link at the top of this e-mail and enter your zip code when prompted
Please call your Senators today. Ask them to Vote YES in support of the HR 6331- the Medicare Improvements for Patients and Providers Act of 2008
Urgent Action Request!
Please call your Senators Today..
Please forward to family members, friends & co-workers- we need as many people as possible to call their Senators today! Ask them to vote " YES " for the Medicare Improvements for Patients and Providers Act before the July 4th recess. As constituents your help is vital. Please help preserve access to gynecologic cancer care, we need your help to ensure continued access to quality healthcare. Cuts to Medicare physicians' payments would endanger the ability of doctors to serve their communities. If not prevented, pending cuts in the Medicare program may cause doctors to have to close their doors. We cannot afford this nor allow this to happen, our lives are dependant upon our physicians. Without access to high quality healthcare our lives and the lives of our loved ones are at stake.
This bill will protect critical access to medical care for millions of Americans and seniors. Please encourage Congress to vote Yes in support of the HR 6331-the Medicare Improvements for Patients and Providers Act of 2008.
We must protect access to our doctors for ALL seniors and the millions of other Americans covered under Medicare. Congress must act before the end of June to protect Medicare patients from losing access to their physicians.
Call or email Congress today! Urge your House member to support HR 6331 - the Medicare Improvements for Patients and Providers Act of 2008.
All House offices can be reached by calling 202-225-3121.
New York Senators:
Senator Charles E. Schumer at (202) 224-6542
Senator Hillary Rodham Clinton at (202) 224-4451
Khrissy Lupinacci
LI OCEANS INC
Long Island Ovarian Cancer Education Advocacy Netwok Support
OCNA 2008 Award Winners! CONGRATULATIONS!
OCNA 2008 Award Winners Cindy Melancon Spirit of Survivorship Award
Hailing from Novi, Michigan, Carolyn Benivegna will be this year’s recipient in honor of her persistent advocacy for promoting awareness for ovarian cancer. Carolyn is an ovarian cancer survivor and the founder of the Ovarian Cancer Alliance of Florida-Gulf Coast. She then moved to Michigan when she made a great impact by working with Governor Jennifer Granholm to declare September as Ovarian Cancer Awareness Month. Carolyn and her husband were also recognized by The Henry P. Tappan Society from the University of Michigan for establishing an endowed Ovarian Cancer Research Fund at UM.
The Voice for Ovarian Cancer Research Award
Taking the trip from Woodbury, NJ will be Karen Mason. After being diagnosed at the age of 49, she quickly discovered that getting involved in the ovarian cancer community was a great coping mechanism. Last Fall Karen was invited to be a member of the Dept of Defense’s Integration Panel where proposals are chosen for funding by the Department of Defense’s Ovarian Cancer Research Program. She also serves as a patient advocate for the Fox Chase Cancer Center ovarian SPORE as a full participating member of their Institutional Review Board evaluating consent forms for clinical trials. Karen is continually involved with NED (no evidence of disease) and is a part-time ICU nurse, wife and mother of two sons.
Rosalind Franklin Excellence in Ovarian Cancer Research Award
Dr. Robert Bast, VP of translational research at MD Anderson in Houston, TX will receive this year’s award for developing the OC125 monoclonal antibody that led to the production of the CA125 test. A major focus on Dr. Bast’s current research is the identification of additional serum tumor markers that would complement CA125 for detection of the disease at early stages. Dr, Bast has published more than 500 articles and chapters, and has edited the textbook, Cancer Medicine and one of the most frequently cited scientists in his field. Dr. Bast continues to care for patients with breast and ovarian cancer and has been listed in the Best Doctors of America and America’s Top Physicians.
Holly's Hope for a Cure will host its first annual golf outing/dinner/auction on August 15, 2008- West Dundee, Ilinois.
Holly's Hope for a Cure
will host its first annual golf outing/dinner/auction on August 15, 2008
Holly had a passion for golf and she would have truly appreciated an event such as this where she could play the game that she genuinely loved and at the same time increase public awareness about ovarian cancer. The proceeds generated from this event will go toward ovarian cancer research for the development of early detection prevention methods, enhanced therapies and ultimately a cure.
Please join us on August 15, 2008. Play a round of golf. Sponsor a hole. Enjoy a nice dinner. Donate and/or bid on an item at the silent auction. The contributions that we receive will be greatly appreciated and are tax deductible to the extent allowed by law. With your help, we can make Holly's hope for a cure a reality for the estimated 20,000 women who will be diagnosed with ovarian cancer this year alone.
For more info contact: info@hollyshopeforacure.com
The President intends to designate Carolyn D. Runowicz, of Connecticut, to be Chairman of the National Cancer Advisory Board
The President intends to designate Carolyn D. Runowicz, of Connecticut, to be Chairman of the National Cancer Advisory Board.
Development of a lay brochure introducing genetic testing and counseling for BRCA1/2 in women of color
Meharry Medical College-Vanderbilt-Ingram Cancer Center Partnership. Partners in eliminating health disparities
Similar pathobiology of ovarian epithelial cancers in diverse populationswith differing incidence rates
ACTION ALERT- Department of Defense Ovarian Cancer Research Program- Need for Congress to Provide $25 million in FY 2009
Electrolux and Keli Ripa support The Ovarian Cancer Research Fund--SHOP ELECTROLUX
Shop Electrolux provide hope!
The Ovarian Cancer Research Fund is the leading organization to fund cutting-edge research focused on finding a method for early detection and, ultimately, a cure for ovarian cancer. Because of these research efforts, there is hope for the women who battle this disease and the people who love them. Electrolux and Kelly Ripa are proud to support this important cause.
Kelly Ripa and Electrolux are committed to raising $500,000 over the next two years to help fund research to fight ovarian cancer.
The Ovarian Cancer Research Fund is the leading organization to fund cutting-edge research focused on finding a method for early detection and, ultimately, a cure for ovarian cancer. Because of these research efforts, there is hope for the women who battle this disease and the people who love them. Electrolux and Kelly Ripa are proud to support this important cause.
Kelly Ripa and Electrolux are committed to raising $500,000 over the next two years to help fund research to fight ovarian cancer.
Urgent Action Alert! Save our Doctors! Anymore medicare cuts will run Oncologists out of business!!!
We can't afford to lose our Oncologists!!
Our Lives depend upon them!
Anymore Medicare cuts will run Oncologists out of business!
Please call your Senators today!! Your phone call CAN MAKE A DIFFERENCE!!!
Senator's phone list: http://www.sgo.org/WorkArea/showcontent.aspx?id=1730
We need your help today with the critical effort to stop the 16 percent cuts that are scheduled for Medicare physician payments over the next two years (a 10.6 percent cut on July 1st followed by an additional 5.4 percent cut in 2009).
This week, Senate leaders will ask the Senate to consider the Medicare Improvements for Patients and Providers Act of 2008 (S. 3101), which has been introduced by Senators Max Baucus (D-MT), Olympia Snowe (R-ME), Jay Rockefeller (D-WV), and Gordon Smith (R-OR). This legislation would block the 10.6 percent cut that, without Congressional action, will go into effect on July 1, 2008; and would also replace the 5.4 percent cut in 2009 with a 1.1 percent increase in Medicare payments for next year.
Before this legislation can be considered, the Senate must invoke cloture, which means it must vote to end debate and move to consideration of the bill. Sixty (60) Senators must vote to invoke cloture. This is, by no means, an easy or guaranteed feat. Your phone calls matter! It is unclear what will happen if we do not get 60 votes for cloture. Your help is absolutely essential in this effort to preserve access to gynecologic cancer care. As soon as possible, but no later than Tuesday, June 17th:
When you call, ask the person who answers the phone to deliver the following message to the Senator:
I am a (Ovarian, Uterine or Cervical Cancer) patient, survivor or loved one in (name your state)
and would like the Senator to vote in favor of cloture and support S. 3101 – The Medicare Improvements for Patients and Providers Act of 2008. When surveying a representative sample of the members of the Society of Gynecologic Oncologists, it was found that if the 10.6% cut goes through on July 1, 2008, 47 percent of those responding would be forced by the cuts in reimbursement to consider curtailing access for Medicare beneficiaries. We need [name of Senator] to vote in favor of cloture on S. 3101.
After calling your Senators, please send an email to SGO Director of Government Relations, Jill Rathbun, at jill_rathbun@galileogrp.com to let us know you have completed your calls. This information will help in the SGO’s efforts on our behalf. We want to stress again how important it is that you call your Senators. We need Senate offices to be inundated with phone calls from SGO Members. Your Senators need to hear from you, their constituent, that their support of this legislation is critical to stopping the cuts and ensuring the continuation of quality care.
4th Annual Indian Island Charity Golf Outing
4th Annual Indian Island Charity Golf Outing
Long Island O.C.E.A.N.S. Ovarian Cancer Education Advocacy and Support
Monday, June 16th 12:00 Check-In 1:00 Shotgun
Sponsorships Opportunities
Dinner Sponsor
Promotional Sign/Banner in prominent Location
Recognition and Publicity in all pre/post events
Plus Tee Sign
$1000.00
Beverage Golf Cart Sponsor
Dinner for 1 person
Promotional Sign on Beverage Cart
$250.00
Lunch Sponsor
Promotional Sign/Banner in prominent Location
Recognition and Publicity in all pre/post events
Plus Tee Sign
$500.00
Tee Sign Sponsor
Promotional sign on golf hole.
$100.00
Practice Range Sponsor
Promotional Sign/Banner in prominent Location
Recognition and Publicity in all pre/post events
Plus Tee Sign
$500.00
Putting Practice Green Sponsor
Promotional Sign/Banner in prominent Location
Recognition and Publicity in all pre/post events
Plus Tee Sign
$500.00
Other types of donations accepted:
Gift Certificates, Gift Baskets, Retail Items, Art, Memberships, etc..
Please write exactly what you would like your sign/banner to display:
Amount Enclosed $______________________
Send payment to Indian Island Country Club Att: Russ Moran:
(Make Checks Payable to Long Island Oceans)
Ph. 631-727-0788 Fax. 631-727-0861 http://www.indianislandcatering.com/
Indian Island Country Club
Att: Russ Moran
661 Riverside Drive Riverhead, NY 11901
10 JUNE, 2008 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS MARSHALL EDWARDS, INC.'S OVATURE TRIAL CONTINUE
Combination Belinostat and Platinum-Based Therapy Shows Efficacy for Relapsed Epithelial Ovarian Cancer: Presented at ASCO
Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
SHARE- Understanding CA 125 Levels
Understanding CA 125 Levels
Although not a recommended screening test, CA 125 is commonly used as partof the diagnosis of ovarian cancer and as a tool used to monitor forrecurrence. But what is this blood test really about? Why is CA 125 not arecommended screening tool? Dr. Thomas Herzog, Director of Gynecologic Oncology, New York-Presbyterian Hospital/Columbia University MedicalCenter, will explain use of CA 125.SHARE Main Office
Monday, June 16th, 6:00 - 7:30 PM
Although not a recommended screening test, CA 125 is commonly used as partof the diagnosis of ovarian cancer and as a tool used to monitor forrecurrence. But what is this blood test really about? Why is CA 125 not arecommended screening tool? Dr. Thomas Herzog, Director of Gynecologic Oncology, New York-Presbyterian Hospital/Columbia University MedicalCenter, will explain use of CA 125.SHARE Main Office
Monday, June 16th, 6:00 - 7:30 PM
Sandy Rich from LI OCEANS - 2008 NYS Women of Distinction"
Dear Friends of Sandy Rich:
I have some very nice news to tell you about Sandy. For her role as one of the founders of "L.I.OCEANS," for serving as its President since its founding, and for the work she's done along with other "OCEANS" members, Sandy was selected by our State Senator Kenneth LaValle as one of New York State's 2008 "Women of Distinction." I'll be joining Sandy in Albany on Tuesday, June 3rd as she's honored at a ceremonyand reception, along with other women from across the state. Sandy and I wanted to share this happy and exciting news with all of you.
With best wishes,
Ed Rich
I have some very nice news to tell you about Sandy. For her role as one of the founders of "L.I.OCEANS," for serving as its President since its founding, and for the work she's done along with other "OCEANS" members, Sandy was selected by our State Senator Kenneth LaValle as one of New York State's 2008 "Women of Distinction." I'll be joining Sandy in Albany on Tuesday, June 3rd as she's honored at a ceremonyand reception, along with other women from across the state. Sandy and I wanted to share this happy and exciting news with all of you.
With best wishes,
Ed Rich
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients
Safety of fertility preservation by ovarian stimulation with letrozoleand gonadotropins in patients with breast cancer: a prospective study
A qualitative study examining psychosocial distress, coping, and social support across the stages and phases of epithelial ovarian cancer.
Estrogen Regulates Snail and Slug in the Downregulation of E-Cadherin and Induces Metastatic Potential of Ovarian Cancer Cells through Estrogen
Body size and risk of epithelial ovarian and related cancers: A population-based case-control study.
Recognition of naturally processed and ovarian cancer reactive CD8(+) T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.
Combination Belinostat and Platinum-Based Therapy Shows Efficacy for Relapsed Epithelial Ovarian Cancer: Presented at ASCO
LI OCEANS bringing light to Ovarian Cancer
A Beacon of Hope for those affected by Ovarian Cancer...LONG ISLAND OVARIAN CANCER EDUCATION ADVOCACY NETWORK SUPPORT.
A Long Island grassroots 501 C Non Profit Organization made up of survivors from the newly diagnosed to the long term survivor. Helping women from Montauk to Manhatten.
Researcher Says She Has Developed A Cancer-Fighting Tool
A researcher who has been experimenting with monoclonal antibodies as a tool for fighting cancer for almost two decades says she has developed a form of the cloned immune system component that could play a role in treating breast, ovarian and other forms of cancer.
Anne Kellogg, associate professor of pathology and laboratory medicine at East Carolina University's Brody School of Medicine, says a monoclonal antibody her team has developed, dubbed DS-6, has shown an ability to attach itself of cancer cells in the lab. This could pave the way for using DS-6 antibodies to deliver potent cancer-killing agents to the malignant cells.
Particular types of monoclonal antibodies can act with great specificity because they are all cloned from the same immune system cell. The antibodies work by attaching themselves to a specific antigen, a protein structure on the cell membrane. This anti-body-antigen interaction sets up disease pathogens for attack by other immune system cells.
The DS-6 antibody Kellogg has developed latches on to tumor cells and enables the whole compound - the antibody and the attached cell-killing agent - to enter the cancer cell. Once inside, the cell-killing agent becomes activated and kills the tumor cell as it divides.
"We can't give such a potent chemotherapy agent on its own because it would be too toxic, but if we can link it to an antibody, it goes inside the tumor cell and is released inside the tumor cell, which is really an amazing feat," Kellogg said.
Kellogg first began working with monoclonal antibodies in the early 1990s.
Kellogg is now working with two drug firms - ImmunoGen and sanofi-aventis - that have expertise in turning monoclonal antibodies into cancer therapies and taking them to clinical trials in humans. These clinical tests must show a proposed drug or other form of treatment are safe and effective before the U.S. Food and Drug Administration will authorize their use by doctors in treating patients.
Anne Kellogg, associate professor of pathology and laboratory medicine at East Carolina University's Brody School of Medicine, says a monoclonal antibody her team has developed, dubbed DS-6, has shown an ability to attach itself of cancer cells in the lab. This could pave the way for using DS-6 antibodies to deliver potent cancer-killing agents to the malignant cells.
Particular types of monoclonal antibodies can act with great specificity because they are all cloned from the same immune system cell. The antibodies work by attaching themselves to a specific antigen, a protein structure on the cell membrane. This anti-body-antigen interaction sets up disease pathogens for attack by other immune system cells.
The DS-6 antibody Kellogg has developed latches on to tumor cells and enables the whole compound - the antibody and the attached cell-killing agent - to enter the cancer cell. Once inside, the cell-killing agent becomes activated and kills the tumor cell as it divides.
"We can't give such a potent chemotherapy agent on its own because it would be too toxic, but if we can link it to an antibody, it goes inside the tumor cell and is released inside the tumor cell, which is really an amazing feat," Kellogg said.
Kellogg first began working with monoclonal antibodies in the early 1990s.
Kellogg is now working with two drug firms - ImmunoGen and sanofi-aventis - that have expertise in turning monoclonal antibodies into cancer therapies and taking them to clinical trials in humans. These clinical tests must show a proposed drug or other form of treatment are safe and effective before the U.S. Food and Drug Administration will authorize their use by doctors in treating patients.
Red Flags for Hereditary Cancers -NY Times
All cancers are genetic in origin. When genes are working properly, cell growth is tightly regulated, as if a stoplight told cells to divide only so many times and no more. A cancer occurs when something causes a mutation in the genes that limit cell growth or that repair DNA damage.